2021 Revenues ($USD) : $1,926,700,000
2021 R&D spend : $359,900,000
2021 Number of Employees : 5,500
Fiscal Year End : 12/31/2020
Key People : Kevin Sayer, chair, president andCEO; Donald Abbey, EVP, quality and regulatory affairs; Andrew Balo, EVP, regulatory strategy, clinical affairs and strategic partnership development; Paulu Flynn, EVP, global revenue; Jake Leach, EVP, chief technology officer; Patrick Murphy, EVP, chief legal officer; Steven Pacelli, EVP and managing director, Dexcom Ventures; Chad Patterson, EVP, global marketing; Barry Regan, EVP, global operations; Shelly Selvaraj, SVP, information technology; Sumi Shrishrimal, SVP, chief risk officer; Sadie Stern, EVP, chief human resources officer; Jereme Sylvain, EVP, CFO.

About the company: One of the industry leaders in continuous glucose monitoring for diabetes management, San Diego-based Dexcom was founded in 1999. Its first approved CGM, a three-day sensor, received an FDA nod in 2006 and the company has continued to develop since. Its first G-series CGM, the G4, was approved in 2014. The latest version to hit the market — the wearable G6 sensor — offers a one-touch applicator for the sleek sensor, which is compatible with smart devices that display real-time glucose data. CEO Kevin Sayer announced in late October that the next-generation G7 system is expected to launch in Europe in the fall while the company is on track to submit for FDA clearance soon. –SW